3,277 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by RWA Wealth Partners LLC

RWA Wealth Partners LLC purchased a new position in AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,277 shares of the company’s stock, valued at approximately $221,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AZN. Sanders Capital LLC purchased a new position in AstraZeneca in the 3rd quarter worth approximately $715,198,000. Manning & Napier Group LLC boosted its holdings in AstraZeneca by 281.2% in the 4th quarter. Manning & Napier Group LLC now owns 2,779,212 shares of the company’s stock worth $187,180,000 after acquiring an additional 2,050,064 shares during the period. Jennison Associates LLC boosted its holdings in AstraZeneca by 5.2% in the 3rd quarter. Jennison Associates LLC now owns 22,946,504 shares of the company’s stock worth $1,553,937,000 after acquiring an additional 1,139,295 shares during the period. abrdn plc boosted its holdings in AstraZeneca by 346.3% in the 4th quarter. abrdn plc now owns 1,420,876 shares of the company’s stock worth $95,696,000 after acquiring an additional 1,102,490 shares during the period. Finally, Barclays PLC boosted its holdings in AstraZeneca by 317.4% in the 3rd quarter. Barclays PLC now owns 1,242,431 shares of the company’s stock worth $84,136,000 after acquiring an additional 944,765 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $75.17 on Friday. The business’s fifty day moving average price is $67.27 and its 200 day moving average price is $66.07. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $75.81. The stock has a market capitalization of $233.06 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.34% and a net margin of 13.30%. The firm had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter last year, the business earned $0.69 earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. Equities research analysts forecast that AstraZeneca PLC will post 4.01 EPS for the current year.

AstraZeneca Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were paid a dividend of $0.965 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a yield of 2.3%. AstraZeneca’s dividend payout ratio (DPR) is 94.61%.

Analysts Set New Price Targets

AZN has been the subject of several research analyst reports. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Morgan Stanley initiated coverage on AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating for the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, BMO Capital Markets increased their target price on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $81.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.